Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

Background The role of androgens on COVID-19 is well established. Proxalutamide is a second-generation, non-steroidal antiandrogen (NSAA) with the highest antiandrogen potency among NSAAs and concurrent regulation of angiotensin-converting enzyme 2 (ACE2) expression and inflammatory response. Proxal...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadegiani, Flavio A, Zimerman, Ricardo A, Fonseca, Daniel N, Correia, Michael N, Muller, Marcio P, Bet, Diego Leonardo, Slaviero, Marcio Rafael, Zardo, Ivan, Benites, Paulo Roberto, Barros, Renan N, Paulain, Raysa W, Onety, Dirce C, Israel, Karla Cristina P, Gustavo Wambier, Carlos, Goren, Andy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712234/
https://www.ncbi.nlm.nih.gov/pubmed/34976549
http://dx.doi.org/10.7759/cureus.20691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712234/
https://www.ncbi.nlm.nih.gov/pubmed/34976549
http://dx.doi.org/10.7759/cureus.20691

Ejemplares similares